SARS-CoV-2感染后的妊娠结局:苏格兰德尔塔与奥密克戎变异株流行期的基于人群队列研究
这项苏格兰全国性基于人群队列研究纳入2021年5月17日至2022年1月31日期间在妊娠期感染SARS-CoV-2的9817名女性(9923次感染,9823次妊娠),以变异株在一般人群中优势流行期(≥50%病例S基因阳性为德尔塔,2021年5月17日至12月14日;S基因阴性为奥密克戎,2021年12月15日至2022年1月31日)作为变异株感染的替代指标。结果显示,与德尔塔优势流行期相比,奥密克戎优势流行期孕妇入住重症监护室风险更低(0.3% vs 1.8%,调整OR 0.25,95%CI 0.14-0.44),感染后28天内早产更少(1.8% vs 4.2%,调整OR 0.57,95%CI 0.38-0.87)。奥密克戎优势流行期死产更少(每1000例分娩4.3 vs 20.3),无新生儿死亡(每1000例分娩0 vs 6.3),但例数过少无法支持调整分析。作者认为,奥密克戎优势流行期感染的孕妇发生早产或入住重症监护室的可能性显著低于德尔塔优势流行期。
要点
- 奥密克戎优势流行期孕妇感染SARS-CoV-2后入住重症监护室风险为0.3%(13/4968),德尔塔优势流行期为1.8%(89/4955),调整OR 0.25(95%CI 0.14-0.44)。
- 奥密克戎优势流行期感染后28天内早产率为1.8%(37/2048),德尔塔优势流行期为4.2%(98/2338),调整OR 0.57(95%CI 0.38-0.87)。
- 奥密克戎优势流行期死产为每1000例分娩4.3例(2/462),德尔塔优势流行期为每1000例分娩20.3例(13/639);奥密克戎优势流行期无新生儿死亡(0/460),德尔塔优势流行期为每1000例分娩6.3例(4/626),例数过少未做调整分析。
- 15例死产中12例发生在感染时未接种≥2剂COVID-19疫苗的孕妇;12例新生儿SARS-CoV-2感染全部发生在母亲感染时未接种≥2剂疫苗者。
- 低Apgar评分(足月儿<7/10)估计不精确:奥密克戎优势流行期5/423(1.2%)vs 德尔塔优势流行期11/528(2.1%),调整OR 0.72(95%CI 0.23-2.32)。
适用人群与场景
- 2021年5月17日至2022年1月31日期间在苏格兰妊娠期确诊SARS-CoV-2感染的9817名女性(9923次感染,9823次妊娠)。
- 以变异株在苏格兰一般人群中优势流行期作为变异株感染的替代:德尔塔优势流行期为2021年5月17日至12月14日(≥50%病例S基因阳性),奥密克戎优势流行期为2021年12月15日至2022年1月31日(≥50%病例S基因阴性)。
诊断标准与关键阈值
- 变异株优势流行期判定:一般人群中≥50%病例S基因阳性为德尔塔优势期,≥50%病例S基因阴性为奥密克戎优势期;敏感性分析采用≥90%优势流行期。
- 主要母亲结局:感染后21天内入住重症监护室或感染日期后28天内死亡。
- 妊娠结局:感染后28天内早产和死产。
- 新生儿结局:出生后28天内死亡、低Apgar评分(足月儿<7/10)或母亲感染后28天内分娩的新生儿SARS-CoV-2感染。
研究设计与关键结果
- 研究类型:全国性基于人群队列研究;人群:苏格兰妊娠期SARS-CoV-2感染者9817名女性,共9923次感染、9823次妊娠;暴露:德尔塔优势流行期感染(4955例)vs 奥密克戎优势流行期感染(4968例);调整因素:母亲年龄、贫困五分位、族裔、孕周和疫苗接种状态。
- 主要母亲结局:奥密克戎优势流行期入住重症监护室风险0.3%(13/4968),德尔塔优势流行期1.8%(89/4955),调整OR 0.25(95%CI 0.14-0.44);感染后28天内无母亲死亡。
- 早产(感染后28天内):奥密克戎优势流行期1.8%(37/2048),德尔塔优势流行期4.2%(98/2338),调整OR 0.57(95%CI 0.38-0.87)。
- 低Apgar评分(足月儿<7/10):奥密克戎优势流行期5/423(1.2%),德尔塔优势流行期11/528(2.1%),调整OR 0.72(95%CI 0.23-2.32),因例数少估计不精确。
- 死产:奥密克戎优势流行期每1000例分娩4.3例(2/462),德尔塔优势流行期每1000例分娩20.3例(13/639);新生儿死亡:奥密克戎优势流行期每1000例分娩0例(0/460),德尔塔优势流行期每1000例分娩6.3例(4/626);例数过少未做调整分析。
- 新生儿SARS-CoV-2感染:德尔塔优势流行期11例,奥密克戎优势流行期1例;15例死产中12例、12例新生儿感染全部发生于母亲感染时未接种≥2剂COVID-19疫苗者。
- 敏感性分析(仅限首次确诊感染、采用≥90%优势流行期)结果与主分析相似。
证据类型、等级与局限
- 证据类型:全国性基于人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,奥密克戎优势流行期感染的孕妇发生早产或入住重症监护室的可能性显著低于德尔塔优势流行期。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence suggests that the SARS-CoV-2 omicron (B.1·1.529) is associated with lower risks of adverse outcomes than the delta (B.1.617.2) variant among the general population. However, little is known about outcomes after omicron infection in pregnancy. We aimed to assess and compare short-term pregnancy outcomes after SARS-CoV-2 delta and omicron infection in pregnancy.
METHODS: We did a national population-based cohort study of women who had SARS-CoV-2 infection in pregnancy between May 17, 2021, and Jan 31, 2022. The primary maternal outcome was admission to critical care within 21 days of infection or death within 28 days of date of infection. Pregnancy outcomes were preterm birth and stillbirth within 28 days of infection. Neonatal outcomes were death within 28 days of birth, and low Apgar score (<7 of 10, for babies born at term) or neonatal SARS-CoV-2 infection in births occurring within 28 days of maternal infection. We used periods when variants were dominant in the general Scottish population, based on 50% or more of cases being S-gene positive (delta variant, from May 17 to Dec 14, 2021) or S-gene negative (omicron variant, from Dec 15, 2021, to Jan 31, 2022) as surrogates for variant infections. Analyses used logistic regression, adjusting for maternal age, deprivation quintile, ethnicity, weeks of gestation, and vaccination status. Sensitivity analyses included restricting the analysis to those with first confirmed SARS-CoV-2 infection and using periods when delta or omicron had 90% or more predominance.
FINDINGS: Between May 17, 2021, and Jan 31, 2022, there were 9923 SARS-CoV-2 infections in 9823 pregnancies, in 9817 women in Scotland. Compared with infections in the delta-dominant period, SARS-CoV-2 infections in pregnancy in the omicron-dominant period were associated with lower maternal critical care admission risk (0·3% [13 of 4968] vs 1·8% [89 of 4955]; adjusted odds ratio 0·25, 95% CI 0·14-0·44) and lower preterm birth within 28 days of infection (1·8% [37 of 2048] vs 4·2% [98 of 2338]; 0·57, 95% CI 0·38-0·87). There were no maternal deaths within 28 days of infection. Estimates of low Apgar scores were imprecise due to low numbers (5 [1·2%] of 423 with omicron vs 11 [2·1%] of 528 with delta, adjusted odds ratio 0·72, 0·23-2·32). There were fewer stillbirths in the omicron-dominant period than in the delta-dominant period (4·3 [2 of 462] per 1000 births vs 20·3 [13 of 639] per 1000) and no neonatal deaths during the omicron-dominant period (0 [0 of 460] per 1000 births vs 6·3 [4 of 626] per 1000 births), thus numbers were too small to support adjusted analyses. Rates of neonatal infection were low in births within 28 days of maternal SARS-CoV-2 infection, with 11 cases of neonatal SARS-CoV-2 in the delta-dominant period, and 1 case in the omicron-dominant period. Of the 15 stillbirths, 12 occurred in women who had not received two or more doses of COVID-19 vaccination at the time of SARS-CoV-2 infection in pregnancy. All 12 cases of neonatal SARS-CoV-2 infection occurred in women who had not received two or more doses of vaccine at the time of maternal infection. Findings in sensitivity analyses were similar to those in the main analyses.
INTERPRETATION: Pregnant women infected with SARS-CoV-2 were substantially less likely to have a preterm birth or maternal critical care admission during the omicron-dominant period than during the delta-dominant period.
FUNDING: Wellcome Trust, Tommy's charity, Medical Research Council, UK Research and Innovation, Health Data Research UK, National Core Studies-Data and Connectivity, Public Health Scotland, Scottish Government Health and Social Care, Scottish Government Chief Scientist Office, National Research Scotland.
参考来源
- Stock SJ, Moore E, Calvert C, et al. Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. Lancet Respir Med. 2022. PMID: 36216011. doi:10.1016/S2213-2600(22)00360-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。